Skip to main content
Download PDF

New Baitouweng decoction combined with fecal microbiota transplantation alleviates DSS-induced colitis in rats by regulating gut microbiota metabolic homeostasis and the STAT3/NF-κB signaling pathway

BMC Complementary Medicine and Therapies volume 22, Article number: 307 (2022) Cite this article

Abstract

Aim of the study

We aimed to elucidate the synergistic effect and potential mechanism of New Baitouweng Decoction (NBD) combined with fecal microbiota transplantation (FMT) in rats with DSS-induced ulcerative colitis (UC).

Materials and methods

Colitis was induced by 5% (w/v) dextran sulfate sodium (DSS) in drinking water for 7 days. NBD or NBD combined with FMT were administered to the colitis rats. Body weight and disease activity index were measured, and the colon histological change was imaged to further examine the efficacy of NBD and FMT. The specific effects of NBD on STAT3/NF-κB signaling pathway and gut microbiota in rats with UC were also investigated.

Results

The efficacy of NBD in combination with FMT was demonstrated by the lower disease activity index scores; increased tight junction proteins expression; and a lower expression of macrophage marker (F4/80) in colon tissues. NBD combined with FMT elevated the concentrations of short-chain fatty acids and inhibited activation of the JAK2/STAT3/NF-κB related proteins. Furthermore, 16SrDNA sequencing indicated that the gut microbiota in rats with UC was perturbed, in contrast to that in healthy rats. After treatment with NBD and FMT, the diversity and abundance of intestinal flora showed clear improvements. Spearman correlation analysis indicated a strong correlation between specific microbiota and fecal concentrations of acetate, propionate and butyrate.

Conclusions

The protective mechanism of NBD combined with FMT may be linked to regulation NF-κB/STAT3 and restoration of the intestinal flora.

Peer Review reports

Background

Ulcerative colitis (UC), a highly prevalent chronic disease, has a complex and unclear pathogenesis, but is considered to be associated with the interaction of genetic factors, the external environment, autoimmune dysfunction and imbalances in the intestinal flora [1]. Monotherapies with aminosalicylates, corticosteroids, immunosuppressive drugs and biological agents have poor efficacy and cause many adverse effects [2]. For aggressive UC, combination therapy at an early stage is the most appropriate treatment [3]. Combination treatment decreases inflammation and regulates the intestinal flora, thus significantly improving ulcerative symptoms [4, 5]. Therefore, combination treatment may be better than monotherapy.

Recent studies have demonstrated that imbalances in the intestinal microflora are a paramount factor in the initiation and progression of UC. Imbalances in the gut microbiota alter microbial diversity, and consequently disrupt symbiosis of microbiota and the host [6]. In addition, the intestinal microbiota derived metabolites could trigger mucosal immune response in colon, thereby disrupting the immune function of the intestinal mucosa and triggering UC [7]. Recently, fecal microbiota transplantation (FMT) has become a pleasurable therapeutic approach for UC. FMT could induce intestinal microecological changes in patients in whom biological and immunosuppressive agents are ineffective, thus enhancing the therapeutic effects of other drugs. A clinical study has indicated that the clinical efficacy of messalamine combined with probiotics in patients with mild-to-moderate UC has greater efficacy than messalamine alone [8]. The improvements in the gut microbiota are believed to affect the regulation of nuclear factor-kappa B (NF-κB), a gene transcriptional regulator crucial in the inflammatory process [9]. When inhibitor of NF-κB (IκB)α undergoes phosphorylation and degradation, the downstream NF-κB signaling pathway is activated, thus initiating target gene transcription and mRNA formation. In addition, the binding of cytokines to the transmembrane receptor induces the phosphorylation of the Janus kinase (JAK), thus stimulating signal transduction and transcriptional activator 3 (STAT3). Activated STAT3 is involved in the gene transcription and protein expression of a variety of inflammatory factors, thereby promoting the formation and persistent exacerbation of inflammation [10]. Thus, regulating JAK2/STAT3/NF-κB signaling is an effective strategy to treat UC.

Traditional Chinese medicine has become a common alternative treatment for UC because of its flexibility and low toxic side effect. Baitouweng decoction containing Pulsatilla chinensis (Bunge) Regel (Baitouweng), Phellodendron chinense C. K. Schneid. (Huangbai), Fraxinus chinensis Roxb. (Qinpi) and Coptis chinensis Franch. (Huanglian), a classical traditional Chinese medicine prescription, originated from “Shang Han Lun” written by Zhang Zhongjing [11]. Several studies have shown that Baitouweng decoction has a variety of effects including anti-diarrhoeal, anti-inflammatory and regulation of intestinal microbiota [12]. However, the development of UC is complex and related to depression and oxidative stress [13, 14]. Previous experiments have concluded that Baitouweng decoction is less than ideal for treating UC [11]. Therefore, based on clinical experience, we added several herbs to Baitouweng decoction to form New Baitouweng Decoction (NBD) for better treatment of UC. NBD has been demonstrated their efficacy in our previous clinical efficacy assessment [15]. Also, our previous study has indicated that a NBD-related herbal granule produced by the Affiliated Hospital of Nanjing University of Chinese Medicine improves experimental colitis by restoring dendritic cell-mediated Th17/Treg balance [16]. NBD, known as Qingchang Huashi Recipe, has been shown to inhibit the inflammatory response of HT-29 cells and macrophage chemotaxis and to reduce NF-κB activation [17]. In addition, both Aucklandia lappa and Paeonia lactiflora existing in NBD, were with anti-depressant and anti-inflammatory properties, which have been shown to have anti-ulcer effect [18, 19]. Paeonia lactiflora Pall and Coptis chinensis could alleviate UC through downregulating the NF-κB/STAT3 signaling pathway [20, 21].

We therefore hypothesized that NBD combined with FMT might improve UC through regulating immunity and the intestinal flora, and might have better effects than either treatment alone. We explored the effect of NBD administration in combination with FMT in a dextran sulfate sodium (DSS)-induced colitis model. Our study validated the possible mechanism of NBD in combination with FMT in DSS-induced UC by examining the JAK2/STAT3/NF-κB signaling pathway. Moreover, we used 16 SrDNA sequencing technology to investigate the structure of gut microbiota in colitis rats under combination therapy.

Materials and methods

Animals

Male Sprague–Dawley rats (weight, 180–220 g) were purchased from Qinglongshan Animal Breeding Farm, Jiangning District, Nanjing, China [license No: SYXK (Su) 2018–0049]. The rats were housed in an air-conditioned room (temperature 24–25 °C, humidity 60–65%) under a 12 h light/dark cycle. Animal experiments were approved by the Ethics Committee of Zhangjiagang TCM Hospital Affiliated with Nanjing University of Chinese Medicine. Ethics No.: AEWC-20201201.

Preparation of NBD

The components of NBD were listed in Table 1. All crude medicines were purchased from the Affiliated Hospital of Nanjing University of Chinese Medicine and identified by Professor Cao Yuan. The above materials were boiled in water (1630 mL) for 1 h after soaking for 1 h. Dregs of the decoction were boiled in boiling water (1304 mL) for 1 h and filtered. The filtrate was combined and concentrated into 1 g crude drug/ml and then stored at 4 °C.

Table 1 The components of NBD
Full size table

Analysis of components in NBD

Concentrated NBD extract was mixed with methanol and then centrifuged at 18,000 g for 10 min. The collected supernatant was subjected to LC-HR-MS analysis. The mobile phase consisted of 0.05% formic acid–water (phase A) and 0.05% formic acid–acetonitrile (phase B). The gradient elution program was as follows: 0–3.2 min, 10% B; 3.2–36 min, 10–90% B; 36–39.1 min, 90% B; 39.1–40 min,90–10% B; and 40–42.1 min, 10% B.

Preparation of fecal microbiota transplantation

Fresh feces from healthy rats were sent to Nanjing Hilshou Biotechnology Co., Ltd. to make capsules. The capsules were 2.7 mm in diameter and dissolved only in the colon. Each capsule contained approximately 15 mg of extract with a bacterial content of 109 cfu/g. Fecal bacteria capsules were cryopreserved at − 80 °C.

Induction of the colitis model in rats and treatment with NBD and FMT

All rats were randomly divided into five groups: control group (Ctrl), DSS group (DSS), DSS + NBD group (NBD,17 g/kg), DSS + FMT group (FMT, 0.5 g/kg) and DSS + NBD + FMT group (NBD,17 g/kg; FMT, 0.5 g/kg). Except for the Ctrl group, which was given water, rats in the other four groups were given 5% dextran sulfate sodium (DSS) (Yeasen Biotech Co., Ltd., Shanghai, China) for 7 days to establish the UC model and then were then provided with water for another 3 days. The DSS + NBD group, DSS + FMT group and the combination group were treated with NBD, FMT and NBD combined with FMT from the second day of DSS intervention respectively. All rats were anesthetized by inhalation of 3% isoflurane (WANQING chemical Glass warey & Instrument Co., Ltd.) and sacrifced by cervical dislocation. After anesthetic euthanasia, the colons were removed, rinsed with phosphate buffered saline (PBS) and measured. The colons and feces were cryopreserved at − 80 °C until further analysis.

Assessment of the disease activity index (DAI) score

During the experiment, daily body weight, stool consistency and the presence of occult blood in feces were documented to illustrate the overall status of the rats [22]. Specifically, five levels of weight loss were recorded, from 0 to 4, indicating no weight loss, < 5% loss, 5–10% loss, 10–20%, and > 20% loss, respectively. Diarrhea was graded on a scale of 0, 2 and 4, indicating normal stools, loose stools and watery diarrhea, respectively. Similarly, hematochezia was quantified with scores of 0, 2 and 4, representing no bleeding, slight bleeding and gross bleeding, respectively.

Histology analysis

Colon sections (approximately 1 cm) were immediately fixed in 10% buffered formalin after being rinsed with ice-cold PBS. Then colon sections were subjected to hematoxylin and eosin (H&E) staining and then examined in a light microscopic to assess histological changes in pathological sections, and the Chiu standard grading was performed in Supplementary Table S1 [23].

Quantitative real-time polymerase chain reaction (qRT-PCR)

Total RNA was extracted from the colon tissues with RNA isolater (Vazyme BioTech Co., Ltd., Nanjing, China) and then subjected to reverse transcription. The cDNA was then used to perform qPCR with ChamQ SYBR qPCR Master Mix (Vazyme BioTech Co., Ltd. in Nanjing, China). A CFX Connect RT-PCR Detection System (Bio-Rad, Hercules, CA, USA) was used to conduct qPCR. Gene expression analysis was performed by using the 2−ΔΔCt method. Primer sequences are shown in Supplementary Table S2.

Western blot analysis

Colonic tissues were completely homogenized with RIPA lysis buffer (Beyotime Biotech Co., Ltd., Shanghai, China). Next, the denaturated proteins were separated with SDS-polyacrylamide gel electrophoresis and electro-blotted onto a polyvinylidene fluoride (PVDF) membrane. The membranes were submerged for 2 h in blocking solution before incubation with the antibodies against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (60004–1-Ig, Proteintech); occludin (13409–1-AP, Proteintech); zona occludens-1 (ZO-1) (21773–1-AP, Proteintech); STAT3 (AP0366, Bioworld); phospho (p)-STAT3 (AP0248, Bioworld); NF-κB p65 (66535–1-Ig, Proteintech); phospho (p)-NF-κB p65 (#3033S, Cell Signaling Technology); JAK2 (ET1607–35, HUABIO); and phospho (p)-JAK2 (ET1607–34, HUABIO). Then, all PVDF membranes were incubated with secondary antibodies, bands were exposed with enhanced ECL solution (Yeasen Biotech Co., Ltd., Shanghai, China) and analyzed in Image J software (National Institutes of Health, USA, 1.8.0). (The blots cut prior to hybridization with antibodies were presented the cropped blots in the manuscript).

Immunofluorescence analysis

First, colonic tissues dewaxed, rinsed and sectioned. The sections were incubated with various primary antibodies. After sections were incubated with secondary antibodies for 1 h, 4′6-diamidino-2-phenylindole (DAPI) staining solution (Beyotime Biotechnology, Shanghai, China) was used. Finally, confocal images were acquired with a LEICA STELLARIS confocal microscope (Leica Camera AG, Germany).

Targeted short-chain fatty acid (SCFA) quantitative analysis

SCFA concentrations (acetate, propionate, butyrate, isobutyrate, valerate and isovalerate) in rat feces were determined by using previously reported methods [24]. Briefly, fecal samples (approximately 50 mg) were added proportionally to 0.5 ml 50% acetonitrile (10 μl solvent per 1 mg stool) and vortexed until fully mixed. The samples were centrifuged at 18,000 g at 4 °C for 5 min. The supernatant (30 μL) was combined with 180 mM 3-nitrophenylhydrazine in 50% acetonitrile (30 μL)and 100 mM EDC-6% pyridine solution (30 μL). The mixture was reacted at 40 °C and maintained for 30 min before centrifuged at 12,000 g at 4 °C for 10 min. Then, 50 μL supernatant collected was diluted to 100 μL with 50% aqueous acetonitrile for liquid chromatograph-mass spectrometer (LC-MS)/MS analysis.

16 SrDNA sequencing and sequencing data analysis

The DNA extracts of colon contents were detected and examined. Then DNA samples were sent to Majorbio Bio-Pharm Technology Co. Ltd. (Shanghai, China) for 16 SrDNA sequencing. The microbial diversity detection was performed on the V3-V4 hypervariable region of the 16SrDNA of the bacteria. The sequencing was performed with the PE300 sequencing strategy on the Illumina MiSeq platform (Illumina, San Diego, USA).

The SILVA (version 138) database was used to compare the bacterial diversity. Observed taxonomic unit (OTU) clustering of non-repeat sequences was performed with Uparse (version 7.0.1090) software, according to 97% similarity, and chimeras were removed. According to the silva138/16s_bacteria species classification database, OTU representative sequences of 97% similar levels were compared with the RDP classifier Bayesian algorithm. With the UniFrac algorithm, principal coordinate analysis (PCoA) was performed to compare the beta diversity of species community among samples. Classifications of bacteria among different groups at the phylum and genus levels were compared using the Kruskal-Wallis rank sum test. The dominant bacterial communities with statistical differences were analyzed using line discriminant analysis (LDA) effect size (LEfSe).

Statistical analysis

All results are expressed as the mean and standard error of mean. One-way analysis of variance was used to analyze the differences between groups. P-values less than 0.05 were considered to indicate statistical significance, reported as follows: *P < 0.05, **P < 0.01 and ***P < 0.001.

Results

Identification of the main constituents of NBD

Figure 1 shows the total ion chromatography of NBD in positive and negative ion modes. A total of 78 components were identified from NBD, including 26 terpenoids, 10 flavonoids, 15 alkaloids, six coumarin components, 12 phenolic components, six organic acids, one naphthoquinone component and two other components. In addition, the identified main chemical components of NBD with analyzed retention times, precise molecular ion peaks and secondary mass spectrometry cleavage fragments are shown in Supplementary Table S3.

Fig. 1
figure 1

Base peak ion flow chromatogram of the major constituents of NBD. (A) Negative ion mode. (B) Positive ion mode

Full size image

NBD combined with FMT alleviated colonic injury in DSS-induced colitis in rats

We evaluated the efficacy of three treatments in a rat model of colitis induced by 5% DSS (Fig. 2A). The body weights of the rats with UC were clearly lower than those of the rats in the Ctrl group (P < 0.001), whereas the body weights of the rats with NBD combined with FMT treatment were significantly closer to those of the rats in the Ctrl group (P < 0.001) (Fig. 2B). Obviously, the weight gain of rats in the combination treatment group was more significant than that in the NBD group and the FMT group (P < 0.05). Furthermore, the DAI score was also markedly decreased by treatment (P < 0.001) (Fig. 2C). The colon length in DSS-induced rats with UC was shorter than that in rats in the Ctrl group, but NBD combined with FMT prevented the DSS-induced colon shortening (P < 0.01) (Fig. 2D,E). Notably, three treatments were effective in alleviating the symptoms of colitis in rats. NBD combined with FMT showed more significant efficacy. Although the pathological staining results of the colon tissues indicated that rats with colitis in the DSS group had symptoms of disruption of epithelial tissues, mucosal layer incompleteness and massive infiltration of inflammatory cells; all these symptoms were markedly ameliorated by NBD and FMT treatment (Fig. 2F). Together, our data indicated that NBD combined with FMT significantly alleviated DSS-stimulated colitis.

Fig. 2
figure 2

NBD combined with FMT attenuated DSS-stimulated UC. (A) Experimental schematic diagram, (B) body weight loss, (C) DAI score, (D,E) shortened colon length, (F) H&E staining and histological colitis score. Data are expressed as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, n = 6

Full size image

NBD combined with FMT up-regulated tight junction protein expression

We measured the representative tight junction proteins and found that the mRNA expression of ZO-1 and occludin were diminished in the DSS group, but combination treatment reversed this response (P < 0.001 or P < 0.01) (Fig. 3A,B). Additionally, the protein expression levels of occludin and ZO-1 decreased in the colon of UC rats but were upregulated by NBD combined with FMT (P < 0.01 or P < 0.05) (Fig. 3C). Interestingly, no significant differences were observed between the NBD group or the FMT group versus the DSS group (P>0.05). Combination treatment upregulated tight junction protein significantly more than NBD and FMT treatment, but there was no significant difference (P>0.05). Moreover, immunofluorescence staining indicated that DSS-induced colitis downregulated the protein expression of ZO-1 and occludin in the colon (P < 0.01 or P < 0.05) (Fig. 3D). However, NBD combined with FMT restored the expression levels of these proteins.

Fig. 3
figure 3

NBD combined with FMT up-regulated tight junction protein expression in colitic rats. (A,B) The expression of occludin (A) and ZO-1 (B) mRNA was down-regulated in the DSS group but up-regulated by NBD combined with FMT, n = 6. (C) Western blotting indicated that NBD combined with FMT elevated the protein expression of occludin and ZO-1 beyond that in DSS-induced rats with UC, n = 3. (D) Representative images of DAPI (blue), occludin and ZO-1 immunostaining (red) in colonic sections (× 200 magnification). Data are expressed as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001

Full size image

NBD combined with FMT inhibited the inflammatory cytokines in DSS-stimulated colitis

To understand the anti-inflammatory effects of NBD and FMT in rats with colitis, we measured the gene expression of pro-inflammatory cytokines and enzymes by PCR. Higher tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, inducible nitric oxide synthetase (iNOS) and cyclooxygenase-2 (COX-2) levels were found in the colitic rats than rats in Ctrl group, but were dramatically downregulated by co-treatment with NBD and FMT (Fig. 4A-E). Compared with the DSS group, NBD significantly reduced the levels of TNF-α and COX-2 (P < 0.05 or P < 0.001), while FMT only downregulated the level of COX-2 (P < 0.001). In addition, the combination treatment was more effective in increasing IL-1β, iNOS and COX-2 levels compared with FMT treatment (P < 0.05 or P < 0.01). However, there was no significant difference in the effect of the combination therapy compared with NBD treatment (P>0.05). Macrophage infiltration is considered a parameter for evaluating the severity of UC [25]. NBD combined with FMT significantly decreased the percentage of F4/80+ cells (Fig. 4F). In a word, our data indicated that NBD combined with FMT in reducing inflammatory cytokines is more effective than either treatment alone.

Fig. 4
figure 4

NBD combined with FMT inhibited inflammatory cytokines in rats with DSS-induced colitis. (A-E) NBD combined with FMT downregulates IL-6 (A), IL-1β (B), TNF-α (C), COX-2 (D) and iNOS (E) mRNA in colonic tissue of rats with UC. (F) Immunohistochemical staining showing F4/80 expression in rats’ colons. Data are expressed as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001

Full size image

NBD combined with FMT suppressed the JAK2/STAT3/NF-κB signaling pathway in vivo

NF-κB regulates the expression of targeted inflammatory mediators, and JAK/STAT activity plays a crucial role in the pathogenesis of UC. We used protein blot analysis to investigate whether NBD combined with FMT might have therapeutic effects via the JAK2/STAT3/NF-κB signaling pathway. As shown in Fig. 5A, DSS-stimulated colitis rats showed a clear trend of upregulation of p-NF-κB p65, p-STAT3 and p-JAK2 proteins, all of which were downregulated in rats treated with three treatments (P < 0.05，P < 0.01 or P < 0.001). However, no significant differences were observed in the expression of JAK2, STAT3 and NF-κB p65 proteins between the NBD combined with FMT group and the other two groups (P>0.05).

Fig. 5
figure 5

NBD combined with FMT suppressed the activity of the JAK2/STAT3/NF-κB pathway in rats with DSS-induced colitis. (A) Western blot images of p-JAK2, JAK2, p-STAT3, STAT3, p-NF-κB, NF-κB and GAPDH. The p-JAK2/JAK2, p-STAT3/STAT3 and p-NF-κB/NF-κB ratios are presented, n = 3. Data are expressed as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001

Full size image

Composition analysis of the gut microbiota

The substantial separation of the Ctrl and DSS group on the two-dimensional coordinate map indicated some differences in the microbial structures between the groups, whereas the distance between samples indicated better reproducibility within the groups (Fig. 6A). The within-group reproducibility was poor in the NBD, FMT and combination group. However, the distance between the FMT group and the combination group was relatively close, and the two groups were distant from the DSS group. The bacterial composition of the FMT group was closest to that of the Ctrl group, followed by the combination treatment group, and that of the NBD group was relatively poor. The composition of the intestinal microflora in rats changed after treatment.

Fig. 6
figure 6

Composition analysis of the intestinal microbiota. (A) PCoA of gut microbiota communities on the basis of OTU levels, n = 5. (B) Bacterial compositions in each group of rats at the phylum level, n = 5. (C-E) Relative abundance of Actinobacteria (C), Patescibacteria (D) and Proteobacteria (E), n = 5. (F) Bacterial compositions in each group of rats at the genus level, n = 5. (G-I) Relative abundance of Lactobacillus (G), Allobaculum (H) and Akkermansia (I), n = 5

Full size image

To further understand the effects of NBD combined with FMT on the gut microbiota, we investigated the composition of the gut microbiota at two taxonomic levels. The microbial community stacking histogram indicated that the fecal microorganisms in rats primarily comprised Firmicutes, Bacteroidetes and Actinobacteria at the phylum level (Fig. 6B). DSS intervention resulted in a clear decrease in the relative abundance of Actinobacteria and Patescibacteria (P < 0.001 or P < 0.05) (Fig. 6C,D). After FMT treatment, their relative abundance was significantly reversed. NBD combined with FMT upregulated the relative abundance of Actinobacteria and Patescibacteria but showed no statistical difference (P>0.05). Furthermore, NBD decreased the relative abundance of Proteobacteria below that in the DSS group (P = 0.127) (Fig. 6E). The genus-level intestinal flora was mainly composed of Lactobacillus, unclassified_f__Lachnospiraceae, Romboutsia and Allobaculum (Fig. 6F). Among these, the relative abundance of Lactobacillus was low in the DSS group (P < 0.001) (Fig. 6G). NBD, FMT and combination therapy alleviated the inhibition of the above bacterial genera (P < 0.001 or P < 0.05). In addition, the relative abundance of Allobaculum increased in the DSS group but decreased after treatment with FMT (P < 0.01) and NBD combined with FMT (P = 0.084) (Fig. 6H). Notably, the effect of FMT was better than that of combination treatment. Compared with that in rats with colitis, the relative abundance of Akkermansia was greater in the group with NBD combined with FMT (P = 0.099) (Fig. 6I).

LEfse analysis of the intestinal flora in rats

LEfSe is a statistical tool enabling the identification of taxa that may distinguish groups on the basis of biostatistical differences. Microorganisms with higher abundance were identified by LDA values greater than 2.0 as the criterion. As shown in our results, 27 taxa were identified in DSS-treated rats (Fig. 7A). A total of 17, 25 and 5 taxa were identified from rats with colitis treated with NBD, FMT, and NBD combined with FMT, respectively. According to the analysis results, g__Allobaculumthe and g__Escherichia-Shigella may be the key bacterial types responsible for the imbalance in the gut flora in the DSS group (Fig. 7B). The difference in the degree of contribution of g_UCG-005, g_Blautia, g__Alloprevotell, etc., was higher in the NBD group, and g__Lactobacillus, g__Romboutsia, g__Lachnospiraceae_UCG-006, p__Actinobacteriota, g__Lachnospiraceae_NK4A136_group, etc. were relatively prominent in the FMT group. Furthermore, g__Clostridium_sensu_stricto_1, g__norank_f__UCG-010, f__Clostridiaceae, etc. in the NBD combined with FMT group were significantly distinct from the microbiota in the other groups. In general, the diversity and composition of the gut microbiota were significantly transformed after the three different treatments.

Fig. 7
figure 7

(A,B) Differences in dominant microorganisms among four groups, on the basis of a cladogram (A) and distribution histogram (B), with an LDA score larger than 2.0 as the criterion, n = 5

Full size image

NBD combined with FMT increased SCFAs in rats with ulcerative colitis

SCFAs, metabolites of the gut microbiota, provide the primary energy source for colonocytes and play a role in intestinal homeostasis by inhibiting inflammation [26]. To confirm whether NBD in combination with FMT might affect SCFA metabolism, we determined the amounts of SCFAs in the colonic contents. The SCFA profiles of the DSS group were completely different from those of treatment groups: the content of acetate, butyrate, propionate and valerate acids were significantly lower in the rats with UC than the Ctrl group (P < 0.001) (Fig. 8A-D). NBD significantly upregulated the levels of propionate and acetate (P < 0.05 or P < 0.01), and FMT increased the level of propionate compared with the results for rats in the DSS group (P < 0.01). Also, combination treatment markedly upregulated the content of butyrate, propionate and acetate above that in rats with DSS-induced colitis (P < 0.001 or P < 0.05). Furthermore, the content of acetate was clearly higher in the combination group than the NBD and FMT groups (P < 0.01). The valerate, isovalerate and isobutyrate concentrations were slightly higher in the combination group than the DSS group, but were not statistically significantly different (P>0.05) (Fig. 8D-F).

Fig. 8
figure 8

NBD combined with FMT increased SCFAs in the colonic feces of rats with colitis to strengthen the intestinal microbial balance. (A-F) The amounts of SCFAs, including acetate (A), propionate (B), butyrate (C), valerate (D), isobutyrate (E) and isovalerate (F), as detected by LC-MS, n = 6. Data are expressed as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. (G) Heatmap showing Spearman correlations between several fecal SCFAs with significant differences and bacterial genera with a coefficient less than 0.05

Full size image

Correlation heatmap analysis was used to determine the potential relationship between altered gut microflora and SCFAs. The result of the correlation heatmap analysis revealed a link between the gut microbiota and SCFAs (Fig. 8G). At the genus level, acetate, propionate and butyrate were positively correlated with Lactobacillus, norank_f__Lachnospiraceae, Enterorhabdus and Roseburia, but were negatively associated with Subdoligranulum, Shuttleworthia, unclassified_f__Ruminococcaceae, Allobaculum and Faecalibacterium.

Discussion

To seek better treatments for UC, therapies such as traditional Chinese medicine, FMT and combination treatment are increasingly being used as adjuvant treatments. NBD, a clinical prescription used in clinical practice in China, is highly effective in light-to-moderate active UC. In addition, a variety of combination treatments have been demonstrated to be superior to monotherapy [27, 28]. Our results suggested that NBD in combination with FMT may have more significant therapeutic effects on colitis than either treatment alone. The body weight, DAI score and the shortening of the colon length were alleviated by NBD and FMT treatment. NBD and FMT mitigated the effects of DSS-induced colitis and may be used to prevent inflammatory bowel disease (IBD) in patients. The combination therapy performed better than the single treatments alone.

The intestinal microbiota plays a pivotal role in maintaining gastrointestinal health. Imbalances in the intestinal microflora can promote the development of UC, thus affecting the renewal of intestinal epithelial cells, intestinal peristalsis and metabolism, and mucosal and immune function [29, 30]. Therefore, investigating the roles of gut microflora in the pathogenesis of UC is crucial, to find effective ways to restore the intestinal microbial balance and alleviate UC. In our results, the diversity of the gut microbial community was significantly diminished in rats with DSS-induced colitis. The PCoA beta diversity revealed that the gut microbiota of colitic rats was clearly separate from that of rats in the Ctrl group, in agreement with a previous report [31]. The human gut microbiota is mainly assigned to four phyla. Rats have similar dominant bacteria to humans. The Firmicutes and Bacteroidetes phyla are the dominant microbiota, followed by the Proteobacteria and Actinobacteria phyla [32]. It was reported that the relative abundance of Actinobacteria significantly decreases with DSS [33]. Actinobacteria, which are gram positive anaerobic bacteria, maintain intestinal homeostasis [34]. In our results, the abundance of Actinobacteria remarkably reduced in the colitic rats, but increased in the FMT group. Meanwhile, FMT increased the relative abundance of the beneficial bacteria Patescibacteria. In our study, the level of Escherichia-Shigella was greater in the DSS group. Shigella, a genus in the Enterobacteriaceae family, is a crucial factor in increasing intestinal permeability and a major pathogen causing intestinal infection [35, 36]. Moreover, FMT treatment increased the abundance of Lactobacillus genera. Lactobacillus, characterized as a common probiotic, can enhance immunity, regulate the intestinal flora, and have anti-cancer and anti-diarrhea effects [37]. One study has shown that Lactobacillus reuteri ameliorates DSS-induced colitis in rats by increasing the colonic mucus thickness [38]. Akkermansia which belongs to the genus Verruca, interacts closely with hosts: it regulates mucus homeostasis of the host, and influences intestinal inflammation and immune system function [39]. All our gut microbiota results suggested that NBD, FMT and combination treatment maintained the gut microbial balance by interfering with different physiological processes through the gut flora. Notably, of the three treatments, FMT had the most significant role in the intestinal microbiota in UC, and was followed by NBD combined with FMT; NBD alone had the least clear role in influencing the intestinal microbiota.

SCFAs, important microbial metabolites, have anti-tumor and anti-inflammatory activity, and play essential roles in ameliorating enteritis, regulating the immune system, promoting intestinal epithelial barrier function and enhancing defense [40]. Therefore, the amounts of SCFAs were determined in this study. NBD and FMT increased the content of SCFAs in the intestinal tract in rats with UC to levels greater than those in the DSS group. Acetate, generated by probiotic Lactobacillus, can maintain the barrier function of the intestinal epithelium and protect the host from lethal infection [41]. Meanwhile, propionate and butyrate maintain intestinal health and delay the development of colitis [42]. Spearman correlation analysis showed that acetic acid, butyric acid and propionic acid were positively associated with Lactobacillus, Roseburia and Enterorhabdus. Our results revealed that Lactobacillus, Roseburia and Enterorhabdus were associated with the increase in SCFAs with NBD and FMT treatment, in agreement with findings from previous reports [43, 44]. We hypothesized that NBD influences the metabolism of gut microbiota, such as SCFA, which may be key to the treatment of UC, and that the exact mechanism of influence needs to be investigated in depth.

The development of colitis is known to increase the production of inflammatory cytokines and proinflammatory enzymes [9]. As expected, in our study, NBD combined with FMT decreased the mRNA expression of TNF-α, IL-1β, IL-6, iNOS and COX-2, thus indicating anti-inflammatory activity in UC. Also, the anti-inflammatory effect of the combination treatment was more pronounced than that of monotherapy. Macrophages, which are the major source of many inflammatory cytokines, spread in tissues throughout the body and are important effector cells of the innate immune system [45]. Tissue macrophages in IBD can significantly increase, thus leading to persistent inflammation. Immunofluorescence indicated that the presence of NBD in combination with FMT significantly inhibited the number of DSS-induced colon macrophages. NBD in combination with FMT inhibited macrophage activation, exerting anti-inflammatory activity.

NF-κB releases pro-inflammatory cytokines and induces proinflammatory enzymes [46]. We found that NBD combined with FMT also inhibited the phosphorylation of NF-κB p65 in the DSS-stimulated colon. Consequently, we hypothesized that the combination of NBD and FMT downregulated the expression of inflammatory cytokines and enzymes in DSS-stimulated colitis, a response potentially associated with inhibition of NF-κB activation. Furthermore, IL-6 activates STAT3, thus leading to elevated levels of anti-apoptotic factors induced by downstream STAT3 [47]. Inhibition of STAT3 ameliorates DSS-induced damage due to colon inflammation by downregulating pro-inflammatory cytokines. STAT3 is a key signaling molecule downstream of the JAK substrates and cytokine receptors, and JAK2/STAT3 signals are the major pathway for transcription factors involved in the pro-inflammatory cytokine response [48]. An important finding in our study was the decreased phosphorylation of JAK2/STAT3 after NBD combined with FMT treatment, thus suggesting that inhibition of the JAK/STAT pathway might be involved in the anti-colitis effect of combination therapy. These findings suggested that NBD in combination with FMT effectively inhibited JAK2/STAT3/NF-κB activation in the experimental UC model. Previous evidence has suggested that, the release of proinflammatory cytokines affects the expression of tight junction proteins [43]. Subsequently, the altered expression of tight junction proteins enhances intestinal permeability, thus leading to an inflammatory cascade [49].

Tight junction proteins are important for function gut barrier and permeability [50]. Accumulating evidence indicates that dysfunctioned intestinal mucosal barrier may lead to the progression of colitis. In our study, DSS-induced UC significantly decreased the colonic occludin and/or ZO-1 expression, but the levels of these proteins significantly increased after NBD and FMT co-treatment. The results suggested that treatment with NBD combined with FMT ameliorated colitis by promoting the repair of intestinal mucosa.

It is worth considering that, on the one hand, NBD treatment may affect the intestinal flora and subsequently the impact of FMT, and may also have a direct effect on inflammatory as well as immunomodulatory signaling pathways, producing more positive changes. On the other hand, FMT provided the opportunity for multiple effects involving bacterial antigens, interactions with the host and synthesis of SCFA when re-establishing the normal microbiome. Therefore, the mechanism of NBD combined with FMT treatment is complex, so the synergistic effects need further study.

Conclusion

We found that NBD, FMT and combination treatment had therapeutic effects in rats with UC. The protective mechanism may be linked to regulation NF-κB/JAK2/STAT3 and restoration of the intestinal flora.

Availability of data and materials

The raw data supporting the conclusions of this article will be made available by the authors upon request. The sequencing data used in this study are stored in NCBI SRA database (SUB11837168). https://www.ncbi.nlm.nih.gov/sra/PRJNA862306.

Abbreviations

DSS:

Dextran sulfate sodium

UC:

Ulcerative colitis

FMT:

Fecal microbiota transplantation

NBD:

New Baitouweng Decoction

NF-κB:

Nuclear factor-kappa B

IκB:

Inhibitor of NF-κB

JAK:

Janus kinase

STAT:

Signal transduction and transcriptional activator

DAI:

Disease activity index

H&E:

Hematoxylin and eosin

PBS:

Phosphate buffered saline

qRT-PCR:

Quantitative real-time polymerase chain reaction

GAPDH:

Glyceraldehyde-3-phosphate dehydrogenase

IL-1β:

Interleukin-1β

IL-6:

Interleukin-6

TNF-α:

Tumor necrosis factor-α

iNOS:

Inducible nitric oxide synthetase

COX-2:

Cyclooxygenase-2

ZO-1:

Zona occludens 1

PVDF:

Polyvinylidene fluoride

p-STAT3:

phospho-STAT3

p-NF-κB:

Phospho-NF-κB

p-JAK:

Phospho-JAK

DAPI:

4′6-diamidino-2-phenylindole

SCFA:

Short-chain fatty acid

LC-MS:

Liquid chromatograph-mass spectrometer

OTU:

Observed taxonomic unit

PCoA:

Principal coordinate analysis

LDA:

Line discriminant analysis

LEfSe:

Line discriminant analysis effect size

IBD:

Inflammatory bowel disease

References

  1. Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative colitis-diagnostic and therapeutic algorithms. Dtsch Arztebl Int. 2020;117(33–34):564–74.

    PubMed  PubMed Central  Google Scholar 

  2. Feuerstein JD, Moss AC, Farraye FA. Ulcerative colitis. Mayo Clin Proc. 2019;94(7):1357–73.

    Article  PubMed  Google Scholar 

  3. Hoekman DR, Stibbe JA, Baert FJ, Caenepeel P, Vergauwe P, De Vos M, et al. Long-term outcome of early combined immunosuppression versus conventional Management in Newly Diagnosed Crohn's disease. J Crohns Colitis. 2018;12(5):517–24.

    Article  PubMed  Google Scholar 

  4. Ishikawa D, Sasaki T, Osada T, Kuwahara-Arai K, Haga K, Shibuya T, et al. Changes in intestinal microbiota following combination therapy with fecal microbial transplantation and antibiotics for ulcerative colitis. Inflamm Bowel Dis. 2017;23(1):116–25.

    Article  PubMed  Google Scholar 

  5. Gao W, Zhang L, Wang X, Yu L, Wang C, Gong Y. The combination of indirubin and isatin attenuates dextran sodium sulfate induced ulcerative colitis in mice. Biochem Cell Biol. 2018;96(5):636–45.

    Article  CAS  PubMed  Google Scholar 

  6. Guo XY, Liu XJ, Hao JY. Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment. J Dig Dis. 2020;21(3):147–59.

    Article  PubMed  Google Scholar 

  7. Ji J, Ge X, Chen Y, Zhu B, Wu Q, Zhang J, et al. Daphnetin ameliorates experimental colitis by modulating microbiota composition and Treg/Th17 balance. FASEB J. 2019;33(8):9308–22.

    Article  CAS  PubMed  Google Scholar 

  8. Tian C, Huang Y, Wu X, Xu C, Bu H, Wang H. The efficacy and safety of Mesalamine and probiotics in mild-to-moderate ulcerative colitis: a systematic review and Meta-analysis. Evid Based Complement Alternat Med. 2020;2020:1–12.

    Google Scholar 

  9. Peng L, Gao X, Nie L, Xie J, Dai T, Shi C, et al. Astragalin attenuates dextran sulfate sodium (DSS)-induced acute experimental colitis by alleviating gut microbiota Dysbiosis and inhibiting NF-kappaB activation in mice. Front Immunol. 2020;11:2058.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77(5):521–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Huangfu S, Dou R, Zhong S, Guo M, Gu C, Jurczyszyn A, et al. Modified Pulsatillae decoction inhibits DSS-induced ulcerative colitis in vitro and in vivo via IL-6/STAT3 pathway. BMC Complement Med Ther. 2020;20(1):179.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Xuan-Qing C, Xiang-Yu LV, Shi-Jia LIU. Baitouweng decoction alleviates dextran sulfate sodium-induced ulcerative colitis by regulating intestinal microbiota and the IL-6/STAT3 signaling pathway. J Ethnopharmacol. 2021;265:113357.

    Article  CAS  PubMed  Google Scholar 

  13. Guazelli CFS, Fattori V, Ferraz CR, Borghi SM, Casagrande R, Baracat MM, et al. Antioxidant and anti-inflammatory effects of hesperidin methyl chalcone in experimental ulcerative colitis. Chem Biol Interact. 2021;333:109315.

    Article  CAS  PubMed  Google Scholar 

  14. Gao X, Tang Y, Lei N, Luo Y, Chen P, Liang C, et al. Symptoms of anxiety/depression is associated with more aggressive inflammatory bowel disease. Sci Rep. 2021;11(1):1440.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Miao Z, Wang X, Zhang X, Zhang Y, Xu Y. Clinical efficacy assessment of new Baitouweng decoction in the treatment of active ulcerative colitis. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2021;29(02):93–6.

    Google Scholar 

  16. Jia J, Zheng K, Shen H, Yu J, Zhu P, Yan S, et al. Qingchang Huashi granule ameliorates experimental colitis via restoring the dendritic cell-mediated Th17/Treg balance. BMC Complement Med Ther. 2020;20(1):291.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Shen H, Liu ZQ, Zhu Q, Zhu L, Zhai JH. Effect of qingchang huash recipe on NF-kappaB/Tolls pathway in ulcerative colitis patients and mechanism study. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi. 2013;33(9):1216–20.

    PubMed  Google Scholar 

  18. Hua YL, Ma Q, Li W, Zhang XS, Cheng XH, Jia YQ, et al. Metabolomics analysis of Pulsatilla decoction on treatment of wetness-heat-induced diarrhea in rats based on UPLC-Q/TOF-MS/MS. Biomed Chromatogr. 2019;33(11):e4629.

    CAS  PubMed  Google Scholar 

  19. Chen Y, Miao Z, Sheng X, Li X, Ma J, Xu X, et al. Sesquiterpene lactones-rich fraction from Aucklandia lappa Decne. Alleviates dextran sulfate sodium induced ulcerative colitis through co-regulating MAPK and Nrf2/Hmox-1 signaling pathway. J Ethnopharmacol. 2022;295:115401.

    Article  CAS  PubMed  Google Scholar 

  20. Gu P, Zhu L, Liu Y, Zhang L, Liu J, Shen H. Protective effects of paeoniflorin on TNBS-induced ulcerative colitis through inhibiting NF-kappaB pathway and apoptosis in mice. Int Immunopharmacol. 2017;50:152–60.

    Article  CAS  PubMed  Google Scholar 

  21. Muluye RA, Bian Y, Alemu PN. Anti-inflammatory and antimicrobial effects of heat-clearing Chinese herbs: a current review. J Tradit Complement Med. 2014;4(2):93–8.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Hu J, Huang H, Che Y, Ding C, Zhang L, Wang Y, et al. Qingchang Huashi formula attenuates DSS-induced colitis in mice by restoring gut microbiota-metabolism homeostasis and goblet cell function. J Ethnopharmacol. 2021;266:113394.

    Article  CAS  PubMed  Google Scholar 

  23. Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low-flow states. I. a morphological, hemodynamic, and metabolic reappraisal. Arch Surg (Chicago, Ill : 1960). 1970;101(4):478–83.

    Article  CAS  Google Scholar 

  24. Han J, Lin K, Sequeira C, Borchers CH. An isotope-labeled chemical derivatization method for the quantitation of short-chain fatty acids in human feces by liquid chromatography-tandem mass spectrometry. Anal Chim Acta. 2015;854:86–94.

    Article  CAS  PubMed  Google Scholar 

  25. Lu N, Wang L, Cao H, Liu L, Van Kaer L, Washington MK, et al. Activation of the epidermal growth factor receptor in macrophages regulates cytokine production and experimental colitis. J Immunol. 2014;192(3):1013–23.

    Article  CAS  PubMed  Google Scholar 

  26. Correa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MA. Regulation of immune cell function by short-chain fatty acids. Clin Transl Immunol. 2016;5(4):e73.

    Article  Google Scholar 

  27. Targownik LE, Benchimol EI, Bernstein CN, Singh H, Tennakoon A, Zubieta AA, et al. Combined biologic and Immunomodulatory therapy is superior to Monotherapy for decreasing the risk of inflammatory bowel disease-related complications. J Crohns Colitis. 2020;14(10):1354–63.

    Article  PubMed  Google Scholar 

  28. Tang S, Liu W, Zhao Q, Li K, Zhu J, Yao W, et al. Combination of polysaccharides from Astragalus membranaceus and Codonopsis pilosula ameliorated mice colitis and underlying mechanisms. J Ethnopharmacol. 2021;264:113280.

    Article  CAS  PubMed  Google Scholar 

  29. Zhang XJ, Yuan ZW, Qu C, Yu XT, Huang T, Chen PV, et al. Palmatine ameliorated murine colitis by suppressing tryptophan metabolism and regulating gut microbiota. Pharmacol Res. 2018;137:34–46.

    Article  CAS  PubMed  Google Scholar 

  30. Lin R, Piao M, Song Y. Dietary Quercetin increases colonic microbial diversity and attenuates colitis severity in Citrobacter rodentium-infected mice. Front Microbiol. 2019;10:1092.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Cui H, Cai Y, Wang L, Jia B, Li J, Zhao S, et al. Berberine regulates Treg/Th17 balance to treat ulcerative colitis through modulating the gut microbiota in the Colon. Front Pharmacol. 2018;9:571.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Ni J, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol. 2017;14(10):573–84.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Yang H, Cai R, Kong Z, Chen Y, Cheng C, Qi S, et al. Teasaponin ameliorates murine colitis by regulating gut microbiota and suppressing the immune system response. Front Med (Lausanne). 2020;7:584369.

    Article  PubMed  Google Scholar 

  34. Binda C, Lopetuso LR, Rizzatti G, Gibiino G, Cennamo V, Gasbarrini A. Actinobacteria: a relevant minority for the maintenance of gut homeostasis. Dig Liver Dis. 2018;50(5):421–8.

    Article  PubMed  Google Scholar 

  35. Bian X, Wu W, Yang L, Lv L, Wang Q, Li Y, et al. Administration of Akkermansia muciniphila ameliorates dextran sulfate sodium-induced ulcerative colitis in mice. Front Microbiol. 2019;10:2259.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Nisa I, Qasim M, Yasin N, Ullah R, Ali A. Shigella flexneri: an emerging pathogen. Folia Microbiol (Praha). 2020;65(2):275–91.

    Article  CAS  PubMed  Google Scholar 

  37. de Vos P, Mujagic Z, de Haan BJ, Siezen RJ, Bron PA, Meijerink M, et al. Lactobacillus plantarum strains can enhance human mucosal and systemic immunity and prevent non-steroidal anti-inflammatory drug induced reduction in T regulatory cells. Front Immunol. 2017;8:1000.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Ahl D, Liu H, Schreiber O, Roos S, Phillipson M, Holm L. Lactobacillus reuteri increases mucus thickness and ameliorates dextran sulphate sodium-induced colitis in mice. Acta Physiol (Oxford). 2016;217(4):300–10.

    Article  CAS  Google Scholar 

  39. Zhang T, Li Q, Cheng L, Buch H, Zhang F. Akkermansia muciniphila is a promising probiotic. Microb Biotechnol. 2019;12(6):1109–25.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Li M, van Esch B, Wagenaar GTM, Garssen J, Folkerts G, Henricks PAJ. Pro- and anti-inflammatory effects of short chain fatty acids on immune and endothelial cells. Eur J Pharmacol. 2018;831:52–9.

    Article  CAS  PubMed  Google Scholar 

  41. Adamberg S, Sumeri I, Uusna R, Ambalam P, Kondepudi KK, Adamberg K, et al. Survival and synergistic growth of mixed cultures of bifidobacteria and lactobacilli combined with prebiotic oligosaccharides in a gastrointestinal tract simulator. Microb Ecol Health Dis. 2014:25.

  42. Cui L, Guan X, Ding W, Luo Y, Wang W, Bu W, et al. Scutellaria baicalensis Georgi polysaccharide ameliorates DSS-induced ulcerative colitis by improving intestinal barrier function and modulating gut microbiota. Int J Biol Macromol. 2021;166:1035–45.

    Article  CAS  PubMed  Google Scholar 

  43. Wang MX, Lin L, Chen YD, Zhong YP, Lin YX, Li P, et al. Evodiamine has therapeutic efficacy in ulcerative colitis by increasing Lactobacillus acidophilus levels and acetate production. Pharmacol Res. 2020;159:104978.

    Article  CAS  PubMed  Google Scholar 

  44. Li Q, Cui Y, Xu B, Wang Y, Lv F, Li Z, et al. Main active components of Jiawei Gegen Qinlian decoction protects against ulcerative colitis under different dietary environments in a gut microbiota-dependent manner. Pharmacol Res. 2021;170:105694.

    Article  CAS  PubMed  Google Scholar 

  45. Oishi Y, Manabe I. Macrophages in inflammation, repair and regeneration. Int Immunol. 2018;30(11):511–28.

    Article  CAS  PubMed  Google Scholar 

  46. Yang L, Liu G, Lian K, Qiao Y, Zhang B, Zhu X, et al. Dietary leonurine hydrochloride supplementation attenuates lipopolysaccharide challenge-induced intestinal inflammation and barrier dysfunction by inhibiting the NF-kappaB/MAPK signaling pathway in broilers. J Anim Sci. 2019;97(4):1679–92.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Chu XQ, Wang J, Chen GX, Zhang GQ, Zhang DY, Cai YY. Overexpression of microRNA-495 improves the intestinal mucosal barrier function by targeting STAT3 via inhibition of the JAK/STAT3 signaling pathway in a mouse model of ulcerative colitis. Pathol Res Pract. 2018;214(1):151–62.

    Article  CAS  PubMed  Google Scholar 

  48. Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020;80.

  49. Ogata M, Ogita T, Tari H, Arakawa T, Suzuki T. Supplemental psyllium fibre regulates the intestinal barrier and inflammation in normal and colitic mice. Br J Nutr. 2017;118(9):661–72.

    Article  CAS  PubMed  Google Scholar 

  50. Zeisel MB, Dhawan P, Baumert TF. Tight junction proteins in gastrointestinal and liver disease. Gut. 2019;68(3):547–61.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This work was supported by the Administration of Chinese Medicine of Jiangsu Province, China (NO. RC201903); National Natural Science Foundation of China (NO. 82104792); Industry university cooperation collaborative education project, Ministry of Education (No. 202102242007); Natural Science Foundation of Jiangsu Province (NO. BK20210134); Project of National Clinical Research Base of Traditional Chinese Medicine in Jiangsu Province, China (No. JD2022SZ19).

Author information

Author notes

  1. Xin Gu and Zhiwei Miao contributed equally to this work.

Authors and Affiliations

  1. Department of Gastroenterology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China

    Xin Gu, Yantian Wang, Yue Yang, Tongtong Yang & Yi Xu

  2. Department of Gastroenterology, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang, China

    Zhiwei Miao

Authors
  1. Xin Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhiwei Miao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yantian Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yue Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tongtong Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yi Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XG and ZM conceived of and designed the experiments and wrote the manuscript; YW and YY performed the experiments; TY and YX analyzed the data. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Yi Xu.

Ethics declarations

Ethics approval and consent to participate

All experiments were performed in accordance with relevant guidelines and regulations. The animal experiment was reviewed and approved by the Ethics Committee of Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine (Ethics No.: AEWC-20201201). All methods are reported in compliance with ARRIVE guidelines for the reporting of animal experiments.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing financial interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gu, X., Miao, Z., Wang, Y. et al. New Baitouweng decoction combined with fecal microbiota transplantation alleviates DSS-induced colitis in rats by regulating gut microbiota metabolic homeostasis and the STAT3/NF-κB signaling pathway. BMC Complement Med Ther 22, 307 (2022). https://doi.org/10.1186/s12906-022-03766-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12906-022-03766-z

Keywords

  • Ulcerative colitis
  • New Baitouweng decoction
  • Fecal microbiota transplantation
  • Gut microbiota
  • STAT3/NF-κB signaling pathway

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us